ConductScience.org, home

Comparison · NCT03150173-sae

O-BMT (Onsite Treatment) vs Enhanced Referral: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. O-BMT (Onsite Treatment) vs Enhanced Referral: serious adverse events. Trial comparisons, record NCT03150173-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03150173-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.02080.003690.109wilson
Risk in group 20.04080.01130.137wilson
Risk difference, group 1 minus group 2-0.02-0.1180.073newcombe hybrid score
Risk ratio, group 1 over group 20.510.04785.45log
Odds ratio, group 1 over group 20.50.04385.7log
Number needed to treat, for one fewer participant with a serious adverse event on O-BMT (Onsite Treatment) than on Enhanced Referral50from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1O-BMT (Onsite Treatment)
Over 2 weeks at the syringe-exchange program, participants in the O-BMT arm will see a buprenorphine provider twice, receive weekly blister packs of medication, and then their care will be transferred to a community health center for maintenance buprenorphine treatment~Onsite treatment: Participants will see a buprenorphine treatment provider who will assess for clinical criteria for opioid use disorder and write a prescription for buprenorphine treatment, which will be filled in a community pharmacy.~Buprenorphine: all participants will receive buprenorphine
148EG000
Group 2Enhanced Referral
In the control arm, participants will receive enhanced referral to a community health center for maintenance buprenorphine treatment~Enhanced referral: Participants will receive an expedited appointment at a community health center for evaluation for buprenorphine treatment~Buprenorphine: all participants will receive buprenorphine
249EG001

Harm

What it counts
Total, serious adverse events
Time frame
24 weeks

Source ClinicalTrials.gov

Trial

Title
Onsite Buprenorphine Treatment at Syringe Exchange Programs
NCT number
NCT03150173
Phases
PHASE2
Conditions
Opiate Addiction
Interventions
Onsite treatment, Enhanced referral, Buprenorphine
Lead sponsor
Montefiore Medical Center
Results first posted
2025-01-14

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03150173-sae